The RLR/NLR expression and pro-inflammatory activity of tissue mast cells are regulated by cathelicidin LL-37 and defensin hBD-2.
Agier. Justyna J; Różalska. Sylwia S; Wiktorska. Magdalena M; Żelechowska. Paulina P; Pastwińska. Joanna J; Brzezińska-Błaszczyk. Ewa E
Key Findings
- Mast cells already have the innate immune receptors NOD1, NOD2, and RIG‑I.
- LL‑37 and hBD‑2 raise the expression of these receptors and cause them to move within the cell.
- Both peptides directly trigger mast cells to release histamine, leukotrienes, chemokines and to migrate, indicating heightened pro‑inflammatory activity.
Practical Outcomes
- LL‑37 appears to make mast cells more sensitive to immune signals, suggesting a possible way to modulate innate immunity. However, the work is purely in vitro with mouse cells, provides no dosage or safety data, and does not translate into a clear protocol for human use. Biohackers should view this as early‑stage mechanistic insight rather than a ready‑to‑apply supplement or therapy.
Summary
The study shows that the natural antimicrobial peptide LL‑37 (and the defensin hBD‑2) can boost the activity of mast cells by increasing the levels of certain immune sensors (NOD1, NOD2, RIG‑I) and making the cells release inflammatory chemicals and move more. This was seen in mouse peritoneal mast cells grown in a dish, not in people.
Abstract
Considering the significance of mast cells (MCs) in the course of various physiological and pathological processes, and the pivotal role of endogenous molecules, i.e., cathelicidins and defensins as multifunctional modulators, the study examines the constitutive and cathelicidin LL-37/defensin hBD-2-induced expression of certain NLRs and RLRs, i.e., NOD1, NOD2, and RIG-I, in fully-mature tissue MCs, and the impact of LL-37 and hBD-2 on MC pro-inflammatory activity. All experiments were carried out in vitro on freshly-isolated peritoneal (P)MCs. qRT-PCR, western blotting, flow cytometry, and confocal microscopy were used to evaluate both constitutive and LL-37/hBD-2-induced expression of NOD1, NOD2, and RIG-I receptors. ROS was determined using H<sub>2</sub>DCFDA, and Boyden microchamber assay was used to define the migratory response. Standard techniques assessed histamine, cysLT, and chemokine generation. PMCs express NOD1, NOD2, and RIG-I constitutively. LL-37 and hBD-2 enhance the expression and induce translocation of the studied receptors and directly activate the pro-inflammatory and migratory responses of PMCs. Observations demonstrate that LL-37 and hBD-2 might augment MC capability and sensitivity to NLR and RLR ligands and strengthen the role of MCs in inflammation.
Study Information
pubmed
2018
2018-08-06T00:00:00.000Z
10.1038/s41598-018-30289-w
23
49